TNF and diabetic kidney disease: In addition, genetic modifications of MSCs, which are also very promising in the context of DKD, include the overexpression of erythropoietin, CXCR4, CTLA4Ig, and IL-10/selectin, as well as the transfection of minicircles containing biological drugs, such as etanercept, which is a TNF-α blocker [182], and transfection of nanoparticles containing iron oxide, polymers, and plasmids [183].